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Background: Adherence to antiretroviral drugs in the treatment of paediatric HIV infection is complicated because
of many factors including stigma and drug intake logistics. It is therefore important to identify children with
non-adherence in order to intervene before they become at risk of developing treatment failure or drug resistance.
The aim of this study was to determine the level of adherence to antiretroviral therapy (ART), measured by
caretaker report, medication return and nevirapine plasma concentration. In addition, the association between level
of adherence and patient’s immune status was compared across the three methods of measuring adherence.
Methods: This was a descriptive cross-sectional study involving HIV infected children aged 2–14 years, on
nevirapine- based antiretroviral treatment for at least six months, attending care and treatment clinic in three
municipal hospitals in Dar- Es- Salaam City. Eligible patients and their accompanying caretakers were consecutively
enrolled after obtaining written informed consent. Structured questionnaires were administered to caretakers to
assess patient’s adherence by caretaker report and medication return whereas a single blood sample for CD4 cell
count/percent and determination of nevirapine plasma concentration was taken from patients on the day of
assessment.
Results: A total of 300 patients and accompanying caretakers were enrolled and the mean patient age (SD) was 8
(3) years. Caretakers’ report and medication return showed good adherence (98% and 97%) respectively. However,
the level of adherence assessed by nevirapine plasma concentration (85%) was significantly lower than caretaker
report and medication return (p < 0.001). The agreement between nevirapine plasma concentration and medication
return and between nevirapine plasma concentration and caretaker report was weak (k = 0. 131) (k = 0. 09)
respectively. Nevirapine plasma concentration below 3 μg/ml was associated with immunosuppression (p = 0. 021)
whereas medication return (>5% of prescribed doses) and caretaker reported missing more than one dose within
72 hours prior to interview were not associated with immunosuppression (p = 0. 474), (p = 0. 569) respectively.
Conclusion: Lower adherence level observed using nevirapine plasma concentration and its association with
immunological response supports the validity of the method and indicates that adherence data obtained from
caretaker report and medication return may overestimate the true adherence in paediatric antiretroviral therapy.* Correspondence: fwmghamba@gmail.com
1Department of Paediatrics and Child Health, School of Medicine, Muhimbili
University of Health and Allied Sciences, P.O. BOX 65001, Dar-Es-Salaam,
Tanzania
Full list of author information is available at the end of the article
© 2013 Mghamba et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Mghamba et al. BMC Pediatrics 2013, 13:95 Page 2 of 7
http://www.biomedcentral.com/1471-2431/13/95Background
Introduction of antiretroviral therapy has resulted in a de-
crease in mortality and morbidity in HIV/AIDS patients
worldwide [1]. Antiretroviral therapy (ART) suppresses
viral load and raises the number of CD4 cells and thus the
quality of life of HIV/AIDS patients on ART is improved.
However, the efficacy of antiretroviral therapy depends on
a high level of adherence [1,2]. Studies have shown that,
for a successful ART, adherence to dosage regimen should
be ≥ 95% [3]. Non-adherence to ART may lead to subopti-
mal drug levels, which may result in therapeutic failure,
deterioration of the immune system and/or emergence of
drug-resistant HIV strains [3,4].
Adherence to antiretroviral therapy in paediatric and
adolescent patients has been reported to be problematic
due to multiple factors. These include the pill burden, poor
palatability, unpleasant flavour, side effects and long term
toxicity [5]. In addition, caregiver type, income, disclosure
of child, caregiver-child communication, caregiver health
belief, depression, stress, stigma, children refuse to take
medications and forgetfulness have also been associated
with non-adherence [6,7]. Caretaker being too busy or fre-
quently away from home and many other logistical chal-
lenges are contributing factors of low adherence to ART in
paediatric patients [8].
In low- and middle- income countries, lack of a simple
and cost-effective gold standard for measuring adherence
to ART is a major challenge for paediatric HIV/AIDS treat-
ment. A number of strategies such as pill count, electronic
monitors, diaries and self-report questionnaires have been
employed. However, each of these methods has limitations
and can provide different estimates of adherence. Import-
antly, these limitations have been reported to be more pro-
nounced in paediatric patients [9,10].
Despite its limitations, antiretroviral drug plasma con-
centration may be considered the gold standard. However,
it is often not feasible, particularly, in resource-poor coun-
tries. In adult patients, the antiretroviral plasma drug con-
centration has been reported to correlate with viral load
response; therefore, giving a more reliable adherence esti-
mate than self reporting [11]. However, to the best of our
knowledge, the literature on the use of plasma antiretro-
viral drug concentration to assess adherence in paediatric
patients is limited.
Although studies done to establish an association between
adherence (measured by self report and medication return)
and immunological response among paediatric HIV/AIDS
patients have shown conflicting findings [12-14], adherence
is a good predictor of effective virological suppression and
subsequent immunological recovery. Some studies have
shown and others have not shown an association between
adherence by self report or medication return and immuno-
logical response. Apart from non-adherence, immunological
suppression has been found to correlate with severity ofmalnutrition, advanced stage of HIV disease (WHO classifi-
cation) and increase likelihood of opportunistic infection
[15,16]. Irrespective of the method of measurement, adher-
ence to antiretroviral treatment is critical in order to reduce
paediatric HIV/AIDS related mortality. We hereby report
the level adherence to antiretroviral therapy and its associ-
ation with immune status among paediatric HIV/AIDS pa-
tients in Dar-Es-Salam.
Methods
This was a descriptive cross-sectional study conducted
from May to October 2011 at three municipal hospitals
(Mwananyamala, Temeke and Amana) in Dar-Es Salaam,
Tanzania. HIV/AIDS patients aged 2-14 years on paediat-
rics nevirapine-based antiretroviral treatment regimen, for
at least six months, and their accompanying caretakers
were enrolled consecutively as they attended HIV care and
treatment clinic. The study protocol was reviewed and ap-
proved by the Muhimbili University of Health and Allied
Sciences (MUHAS) Ethical Review Committee and per-
mission to conduct the study was obtained from the re-
spective District Medical Officers. Only eligible patients
whose accompanying caretaker gave a written informed
consent were enrolled and patients not on nevirapine-
based regimen were excluded. Also excluded were patients
on medications that are known to induce/inhibit nevira-
pine metabolizing enzymes (CYP 2B6 and CYP3A4) such
as rifampicin, fluconazole, and ketaconazole. An assent
was also obtained from patients aged 12 years and above
before inclusion into the study.
Study procedure
A structured questionnaire was used to assess adherence
to antiretroviral therapy and information on the patient’s
concurrent use of other drugs and co-morbidity was col-
lected. In addition, patient’s medical history including his-
tory of illness in the previous visit, history of cough, fever,
ear discharge, vomiting of medication, skin or oral lesion
was taken. The duration of antiretroviral therapy, the time
at which the early morning dose prior to assessment was
taken, and the type of ART regimen in use were checked
and recorded. Socio-demographic characteristics of the
caretaker were also recorded. Screened patients in the
study were on ART regimens in line with the Tanzania
guideline for diagnosis and management of HIV infection.
All patients were on Paediatric Fixed Dose Combination
(FDC) tablets, and patients who were selected into the
study, were either on: Triomune Baby, FDC 6® (50 mg ne-
virapine, 6 mg stavudine, 30 mg lamivudine) or Triomune
Junior, FDC 12® (100 mg nevirapine, 12 mg stavudine, 60
mg lamivudine) or a fixed-dose combination containing
60 mg Zidovudine, 30 mg lamivudine, and 50 mg nevira-
pine. The nevirapine dose was 160 - 200 mg per m2 per
dose given twice a day [17]. However, the fixed-dose
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weight as recommended by WHO. Thus children weighing
12–13.9 kg received 200 mg; 13–19.9 kg received 250 mg;
19.9 - 24.9 kg received 300 mg and those weighing ≥25 kg
received 400 mg of nevirapine per day in two divided
doses. A detailed physical examination was then performed
by the attending clinician and this included body weight,
height and mid upper circumference measurement.
A single blood sample for determination of nevira-
pine plasma concentration and CD4 cell count/per-
centage was collected and divided into two aliquots.
The aliquot for CD4 cell count/percentage was placed
in Ethylenediaminetetraacetic Acid (EDTA) tubes and
transported to the Muhimbili HIV Reference Labora-
tory for flow cytometry whereas the aliquot for nevira-
pine plasma concentration was placed in heparinised
tubes and immediately centrifuged to obtain plasma.
The plasma samples were transferred into cryovials,
transported in a cool box to the MUHAS-Sida Bioanalytical
Laboratory and stored at −80°C until assay. Determination
of nevirapine plasma concentration was done using a pub-
lished reversed phase High Performance Liquid Chroma-
tography (HPLC) method [18]. Before analysis of patient
samples, the method was validated with respect to accuracy
and precision. The method was also tested for lack of inter-
ference of endogenous substances and the components of
cotrimoxazole (sulphamethoxazole and trimethoprim) since
most patients are given cotrimoxazole before or during
ART.
Assessment of adherence
Adherence to antiretroviral therapy was assessed using
caretaker report, medication return and nevirapine plasma
concentration. The caretaker reported the total number of
missed doses for the past three days. Adherence was con-
cluded when no more than one dose was missed three days
prior interview. A patient assessed by medication return
was categorized as adherent when less than 5% of the medi-
cations were returned on the day for a refill and the level of
adherence was calculated as percentage of prescribed dose
not returned. Nevirapine trough plasma concentration of 3
μg/ml has been shown to be the cut off for efficacy [19].
Therefore, nevirapine plasma concentration ≥ 3 μg/ml was
categorized as adherence. Adherence obtained by nevira-
pine plasma concentration as an objective method was
compared with subjective methods, care-taker’s report and
medication return.
Sample size
The sample size was calculated based on the comparison of
two independent proportions from groups of unequal sam-
ple size (good immune status versus immunosupressed).
Since no similar previous study could be traced in the lit-
erature, the proportion of patients with good immunestatus (π1) was assumed to be 50% and the proportion of
immunosupressed children (π0) to be 30%. Taking 5% sig-
nificance level, and an 80% power to detect a significant dif-
ference, the minimum sample size was calculated to be 200
and thus a total of 300 patients (100 from each hospital)
was recruited into the study.
Predictor variables
The predictor for immune status in this study were adher-
ence and non-adherence measured by caretaker report,
medication return and nevirapine plasma concentration.
Possible confounders
The possible factors that could affect adherence to ART
and immune status in this study were: demographic factors
of caretaker (Age, sex, occupation, marital status, level of
education, religion); age and sex of the patient; caretaker
type; disclosure of child; and duration of ART. Others in-
cluded clinical factors such as infections (e.g. pneumonia,
diarrhoea, malaria, otitis media, oral lesion, stage of HIV
disease and nutritional status.
Outcome variables
In this study, immune status was defined and graded
according to WHO immunological classification [17]. Good
immunity was defined as the CD4 cell % >30% for patients
under 5 years or CD4 cell count >500/μl for patients above
5 years. CD4 cell % or count below the ones quoted above
was defined as immunosuppression.
Statistical analysis
Data were entered in the Epi info software version 3.5.1
and then exported to the Statistical Package for Social Sci-
ence (SPSS) version 15 for analysis. Mean and standard de-
viations were calculated for continuous variables whereas
percentages were calculated for categorical variables. All
continuous variables were categorized and analyzed using
the Chi square test or Fisher’s exact test and P value < 0.05
was considered significant. The association was measured
by Odds ratio (OR). Factors with P-value 0.2 or less at bi-
variate analysis were selected for further multivariate ana-
lysis and entered into a logistic regression model. The
model was used to assess the independence and strength of
association of predictive factors of interest using CD4 count
as the outcome variable, as well as to control for possible
confounders of the main predictor (adherence) and out-
come. A difference of at least 10% between adjusted odds
ratio and the crude odds ratio was considered confounding.
The Kappa statistic was used to assess agreement between
adherence measures (caretaker report, medication return
and nevirapine plasma concentration). The sensitivity, spe-
cificity, positive predictive value and negative predictive
value were used to determine the validity and precision,
using CD4 cell count/percentage, to compare the three
Table 1 Level of adherence to ARV among HIV children
Variable Frequency (N) Proportion 95% CI*
1. Medication return
≤5% 291 0.97
>5% 9 0.03 0.02-0.06
2. Caretaker self report
Never missed 295 0.98
Missed 5 0.02 0.01-0.03
3. Nevirapine conc
≥3 μg/ml 254 0.85
<3 μg/ml 46 0.15 0.12-0.20
* Confidence interval.
Figure 1 Proportion comparison of adherence.
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tion return and plasma drug concentration) to detect ad-
herence and non adherence.
Results
Study population
A total of 300 participants met inclusion criteria and
were recruited into the study. The majority of these pa-
tients were above five years (81.3%) of age. The mean
age (SD) was 8 (3) years and almost half of the partici-
pants were female (50.7%).
The majority (77%, n = 231) had advanced stage of HIV
disease and almost half were malnourished. Of the 176
children assessed for disclosure only 23.9%, (n = 42) with
age of 7–14 years knew their HIV status. Most of the chil-
dren (90.7%, n = 272) were on ART for more than one year
and 31.7% (n = 95) had infections. More than three quar-
ters (77.7%, n = 233) of children were immunosuppressed
at baseline while only 28% (n = 84) were immunosup-
pressed when current CD4 cell %/ count was checked.
Socio-demographic characteristics of caretakers
The mean age of the caretakers was 35.9 ± 10.7 years ran-
ging from 18 to 70 years. Of the 300 caretakers, 88.3%
(n = 265) were female and only 21% (n = 63) had beyond
primary school education. Most of the caretakers had pri-
mary school education (68.7%, n = 206). The majority of
caretakers (58.7%, n = 176) were mothers of patients.
Among the 300 caretakers 36% (n = 138) were married and
only 16.7% (n = 50) were employed.
Level of adherence
As many as 85% of the participants (n = 254) were adherent
when assessed by nevirapine concentration whereas the pro-
portion of adherence assessed by medication returned and
caretaker report were (97%, n = 291), (98%, n = 295) respect-
ively (Table 1). The level of adherence assessed by nevirapine
plasma concentration was significantly lower (85%) than that
suggested by medication return and caretaker report (both
p < 0.01). However, there was no significant difference in the
level of adherence by caretaker report and medication return
(p = 0. 06) (Figure 1). Agreement between nevirapine plasma
concentration and caretaker report and between nevirapine
plasma concentration and medication return was weak
(k = 0. 01) (p = 0.77), (k = 0.13) (p = 0.002) respectively
(Table 2).
Adherence measures and immune status
Nevirapine plasma concentration < 3 μg/ml was associ-
ated with immunosuppression (OR = 2.84, p = 0.002)
whereas adherence by caretaker report as well as by
medication report were not associated with immuno-
suppression (OR = 0.64, p = 0.569) and (OR =1.75, p =
0.474) respectively (Table 3). Compared with immunestatus (CD4 count/percentage), the sensitivity of ne-
virapine plasma concentration for detecting inad-
equate adherence was higher (11.1%) compared to
medication return and caretaker report (4.7% and
1.2% respectively).
Other factors associated with immune status
Other factors associated with immunosuppression were
the age of the patient ,2-5 years (OR = 5.52, CI 2.8-10.6) ,
patients on antiretroviral therapy for less than one year
(OR = 6.27, CI 2.69-14.63) and infections (OR = 2.00, 1.18-
3.37). These infections included pneumonia, Otitis media,
oral lesion and skin lesion.
Multivariate analysis of the factors associated with
immune status
The final multivariate analysis was performed by a back-
ward elimination procedure taking into account the bio-
logical knowledge about independent variables and how
they relate to immune status. After controlling for con-
founders, nevirapine plasma concentration <3 μg/ml
was independently associated with immunosuppression
(OR = 2.47, CI = 1.15–5.33). Duration of antiretroviral
therapy (ART) less than a year was also independently
associated with immunosuppression (OR = 6.79. CI = 2.
Table 2 Agreement between nevirapine plasma






















Table 4 Multivariate analysis of the factors associated
with immune status (N = 300)
Variables OR (95%CI*) P-value
Nevirapine plasma conc
<3 μg/ml 2.47(1.15-5.33) 0.021
≥3 μg/ml
Age of the child







≤1 year 6.79(2.69-17.16) 0.0001
>1 year 1
OR- Odd Ratio * Confidence interval.
Mghamba et al. BMC Pediatrics 2013, 13:95 Page 5 of 7
http://www.biomedcentral.com/1471-2431/13/9569–17.16). The potential confounders of nevirapine
plasma concentration were patients with young age (2-
5 years) (OR = 6.00, CI =2.96–12.17) and infections
(OR = 2.00, CI = 1.01–3.41) (Table 4).Discussion
In this study, we have estimated the level of adherence
to ART in paediatric HIV/AIDS patients using two com-
monly employed methods (caretaker report, and medica-
tion return) and one seldom used method (drug plasma
concentration). Our data are similar to what has been
reported in adult patients and suggest that care taker re-
port and medication return may overestimate the true
level of adherence. Adherence to Antiretroviral therapy
in paediatrics is critical in order to maximize the benefit
of medication. Inadequate adherence is associated with
immunological, and virological failure; drug resistance,
and treatment failure [4]. In our study, high adherence
levels to ART by caretaker report (98%) and medication
return (97%) were observed. However, adherence level by
nevirapine plasma concentration was significantly lowerTable 3 Bivariate analysis of adherence measures and
immune status (N = 300)
Immune status
Variable Immunosuppression Normal OR CI P
Valuen (%) n (%)
1. Caretaker report
Missed 1(20.0) 4(80.0) 0.64 0.07-5.79 0.569
Not missed 83(28.1) 212(71.9) 1
2. Medication return
>5% 4(40.0) 6(60.0) 1.75 0.48-6.36 0.474
≤5% 80(27.6) 210(72.4) 1
3. Niverapine plasma concentration
<3 μg/ml 22(47.8) 24(52.2) 2.84 1.49-5.41 0.002
≥3 μg/ml 62(24.4) 192(75.6) 1(85%) than the level estimated by caretaker report
and medication return. Our findings are in agree-
ment with those obtained in Cameroon in which a
comparable proportion of patients were found to be
adherent to ART by using nevirapine plasma concen-
tration method [11].
In addition, there was a weak agreement in estimating ad-
herence between nevirapine plasma concentration method
and care taker report (kappa 0.09) as well as medication re-
turn (kappa 0.131). This means, non-adherent patients were
classified as adherent by caretaker report and medication
return methods whereas in fact, were non-adherent.
Using medication returns and care taker report, our data
show that only 3% of the patients were non adherent to
antiretroviral medication. These findings are similar those
reported from Uganda where the level of adherence
assessed using medication return and caretaker reporting
was relatively high [20]. Nevirapine plasma concentration
seems to give a better estimation of adherence to ART than
caretaker report and medication return. Our study found a
strong association between nevirapine plasma concentra-
tion (< 3 μg/ml) and immunosuppression. In addition, there
was no association between medication return and im-
munosuppression. Similar findings have been reported
from South Africa [13]. Furthermore, our study shows that
caretaker report and medication return have low sensitivity
to detect non adherent children compared to nevirapine
plasma concentration, which could detect a higher propor-
tion of non adherent children. At the moment, medication
return and caretaker report, are methods used routinely for
measuring adherence in paediatric patients on ART in HIV
care and treatment clinics. This means that, a great deal of
non-adherent patients receive suboptimal treatment and
this has clinical implication in terms of treatment outcome
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resistance.
Our data show that nevirapine plasma concentration
may be a better predictor of adherence and correlates well
with the immunological response compared to medication
return and caretaker report. However, lack of ability to de-
tect missed dose through determination of drug concen-
tration by HPLC, for drugs with a long half-life, such as
nevirapine is one of the limitations of our study. Failure to
detect missed doses would underestimate non adherence
to ART in some patients. In addition, only a single blood
sample was taken, and the time of last dosing was
dependent on the authenticity of the caretaker’s reporting,
which may not be guaranteed. It is possible that some of
the caretakers or older children damped medication due
to reasons previously reported [7] so as to create the im-
pression of good adherence on the day of refill. Damping
of pills to create false positive adherence has previously
been reported [21].
In this study, non-adherence by nevirapine plasma con-
centration was found to be 15%, which is alarming when
considering the management of HIV/AIDS in children.
However, it is important to note that, blood drug concen-
tration can be affected not only by the level of adherence
but also drug bioavailability, individual’s metabolic capacity,
timing of drug intake and the time the blood sample for
determination of drug concentration is taken as well as
having diarrhoea or vomiting immediately after drug ad-
ministration. In our study, no patient was reported to have
vomited or experienced diarrhoea after drug intake. It is
unlikely that the low plasma concentrations observed in
some patients have been due to poor nevirapine bioavail-
ability since, in all patients, we used same paediatric fixed-
dose combination tablets obtained from WHO prequalified
manufacturers. In this study, all patients who were using
other drugs, which could interact with nevirapine, such as
ketoconazole and rifampicin were excluded precluding the
possible influence of enzyme inhibition or induction on the
observed plasma concentration. However, in this study, the
patients were not genotyped with respect to CYP 3A and
2B6 to rule out the role of indivudual’s metabolic capacity
that could influence the plasma concentrations of nevira-
pine. A recent Pharmacogenetics study conducted in
Tanzanian adults indicated the frequencies of CYP2B6 geno-
types to be 37%, 45% and 16% for homozygous wild type
(fast metabolizers), heterozygous (intermediate) and homo-
zygous mutated (poor metabolizers) repectively [22]. This
implies that the obtained nevirapine plasma concentrations
in some of our patients could have been influenced by the
patient’s 2B6 activity. It is possible that observed high or low
nevirapine concentrations were due to delay of blood sam-
pling or drug intake, we recorded the last time of drug in-
take prior blood sampling and the time of blood sampling.
We noted that the mean sampling interval was 4 ± 2 hourspost intake of the last dose, which did not significantly devi-
ate from the study protocol.
Despite the above limitations, our findings support the
use of drug plasma concentration as an objective method
for determining adherence to ART where feasible. This
would complement the information obtained from care
taker report and medication returns particularly in groups
of patients showing poor treatment response. Deter-
mination of plasma drug concentration to estimate ad-
herence is often not feasible but nevirapine plasma
concentration may be useful and cost-effective in the
setting of a pharmacovigilance program with adher-
ence monitoring where this may be limited to patients
at sentinel sites and at regular intervals. Apart from es-
timating adherence, nevirapine plasma concentration
may be used in the analysis of non-response that may
lead to detection of early signs of drug resistance par-
ticularly in patients with well characterised genotypes
of important metabolizing enzymes.
Conclusion
Lower level of adherence by nevirapine plasma concentra-
tion and its association with immunological response sup-
ports the validity of the method and indicates that the
adherence estimate obtained by care takers’ reporting and
medication returns may be an overestimate of true adher-
ence level. This may have important clinical implications
in antiretroviral therapy. Therefore, nevirapine plasma
concentration may be a good predictor of adherence and
should be considered where it is feasible and cost-effective.
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